| 引用本文:张至惠1，胡述博1，王志峰1，李帆2.补肾活血汤联合曲妥珠单抗治疗Her-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响[J].世界中医药,2019,(04):. |
|
| 补肾活血汤联合曲妥珠单抗治疗Her-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响 |
| Clinical Effects of Bushen Huoxue Decoction Combined with Trastuzumab in Treating Her-2 Positive Advanced Breast Cancer and Its Effects on Patient's Immune Function |
| 投稿时间：2018-10-01 |
| DOI：10.3969/j.issn.1673-7202.2019.04.044 |
| 中文关键词: 补肾活血汤 曲妥珠单抗 人表皮生长因子受体2 乳腺癌 肝肾阴虚型 疗效 免疫功能 |
| English Keywords:Bushen Huoxue Decoction Trastuzumab Her-2 Breast cancer Liver and kidney yin-deficiency syndrome Efficacy Immune function |
| 基金项目:河南省科技攻关计划项目(201703235) |
|
| 摘要点击次数: 591 |
| 全文下载次数: 541 |
| 中文摘要: |
| 目的:研究补肾活血汤联合曲妥珠单抗治疗人表皮生长因子受体2(Her-2)阳性晚期乳腺癌(肝肾阴虚型)临床疗效及对患者免疫功能的影响。方法:选取2015年3月至2018年2月驻马店市中医院收治的Her-2阳性晚期乳腺癌患者82例作为研究对象,按照随机数字表法分为对照组与观察组,每组41例,对照组采用注射用曲妥珠单抗治疗,观察组采用补肾活血汤联合注射用曲妥珠单抗治疗。观察并比较不同治疗方式对2组的临床疗效、不良反应以及对患者免疫功能的影响。结果:1)观察组治疗后总有效率显著高于对照组(92.69% vs 75.61%)(P<0.05);2)2组治疗前CD4+、CD8+及CD4+/CD8+水平比较，差异无统计学意义(P>0.05);观察组治疗后CD4+、CD4+/CD8+水平均高于治疗前,CD8+水平低于治疗前(P<0.05);对照组治疗后CD4+、CD4+/CD8+水平均低于治疗前,CD8+水平高于治疗前(P<0.05);观察组治疗后上述指标水平改善程度大于对照组(P<0.05);3)2组治疗前免疫球蛋白A(IgA)、免疫球蛋白G(IgG)及免疫球蛋白M(IgM)水平比较，差异无统计学意义(P>0.05);观察组治疗后IgA、IgG及IgM水平均高于治疗前(P<0.05);对照组治疗后IgA、IgG及IgM水平均低于治疗前(P<0.05);观察组治疗后上述指标水平改善程度大于对照组(P<0.05);4)观察组胃肠道反应、心脏毒性、肝功能损伤、骨髓抑制等不良反应发生明显低于对照组(P<0.05)。结论:补肾活血汤联合曲妥珠单抗治疗Her-2阳性晚期乳腺癌患者可改善近期临床疗效及免疫功能,且安全性好。 |
| English Summary: |
| To investigate clinical effects of Bushen Huoxue Decoction combined with trastuzumab in treating epidermal growth factor receptor 2 (Her-2) positive advanced breast cancer (liver and kidney yin-deficiency syndrome) and its effects on patient's immune function.Methods:A total of 82 patients with Her-2 positive advanced breast cancer admitted to Zhumadian TCM Hospital from March 2015 to February 2018 were enrolled and divided into the control group and the observation group according to the random number table method，with 41 cases in each group.The control group was treated with Trastuzumab Injection.Based on this，the observation group received Bushen Huoxue Decoction.Then the clinical efficacy，adverse reactions and immune function of the 2 groups were observed and compared.Results:1)The total effective rate of the observation group was significantly higher than that of the control group (92.69% vs 75.61%，P<0.05).2)The CD4+，CD8+ and CD4+/CD8+ levels had no difference between groups before treatment (P>0.05)，and the CD4+ and CD4+/CD8+ levels increased in the observation group and decreased in the control group after treatment (P<0.05)，while the CD8+ levels decreased in the observation group and increased in the control group after treatment (P<0.05).The amelioration degree of the above indicators in the observation group was higher than that of the control group (P<0.05).3)The levels of IgA，IgG and IgM had no difference between groups before treatment (P>0.05)，which were increased in the observation group and decreased in the control group after treatment (P<0.05)，and the amelioration degree of the above indicators in the observation group was higher than that of the control group (P<0.05).4)The incidence of adverse reactions such as gastrointestinal reactions，cardiotoxicity，liver function damage and myelosuppression in the observation group was significantly lower than that in the control group (P<0.05).Conclusion:Bushen Huoxue Decoction combined with trastuzumab can effectively and safely ameliorate the short-term efficacy and immune function for patients with Her-2 positive advanced breast cancer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
